Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
MALVERN, Pa. -On Tuesday, Neuronetics Inc. (NASDAQ:STIM) reported mixed fourth quarter results, with revenue exceeding expectations but earnings falling short of estimates.
The company’s shares were up 5.87% in premarket trading following the release.
The medical technology company posted a loss of $0.33 per share for Q4, wider than the $0.24 loss analysts were expecting. However, revenue came in at $22.5 million, surpassing the consensus estimate of $18.97 million and representing 11% YoY growth.
For the full year 2024, Neuronetics reported revenue of $74.9 million, up 5% compared to 2023. The company’s U.S. treatment session revenue was $50.8 million for the year.
"2024 was a defining year for Neuronetics as we’ve strategically transformed our business model and market position," said CEO Keith J. Sullivan. He noted the company expanded its Better Me Provider network and acquired Greenbrook TMS, creating an "unparalleled TMS treatment platform."
Looking ahead, Neuronetics provided Q1 2025 revenue guidance of $28-30 million and full year 2025 revenue guidance of $145-155 million, both in line with analyst expectations.
The company expects to achieve cash flow positivity in Q3 2025 and is targeting double-digit revenue growth for the year. Neuronetics also said it has executed actions to realize over $21 million of the targeted $22 million in expected annualized cost synergies related to the Greenbrook acquisition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.